semaglutide original use Obesity Drugs Are Moving Way Past Ozempic Novo's Rybelsus gains FDA expansion

Starting January 2026, you may have an alternative to the injection: CV Risk Reduction: Alternative Coverage Pathway Wegovy is the only obesity medication FDA-approved to reduce cardiovascular risk (March 2024)

It is distinct from Rybelsus, which is also oral semaglutide but is licensed at lower doses (3 mg, 7 mg, 14 mg) for type 2 diabetes rather than weight loss

Patients should be educated about the symptoms of pancreatitis severe abdominal pain that may radiate to the back, nausea, and vomiting and instructed to seek immediate medical attention if these symptoms occur

In REDEFINE 1, adults with obesity or overweight (without diabetes) treated with CagriSema had a mean body weight reduction of 20.4% at 68 weeks under the treatment-policy estimand, compared with 3.0% on placebo

Food makes me gain weight